Aberrant Hypermethylation-Mediated Suppression of PYCARD Is Extremely Frequent in Prostate Cancer with Gleason Score ≥ 7
Table 1
Relationships between PYCARD methylation or immunostaining and clinicopathological parameters.
Characteristics
Total ()
Promoter methylation
value
Immunostaining (T)
value
Immunostaining (N)
value
Yes
No
Yes
No
Yes
No
Total
45
5
4
46
40
10
Gleason score (Grade Group)
0.0063 (0.002)
0.7726 (0.9134)
0.1759 (0.1463)
6 (group 1)
4
1
3
0
4
2
2
7 (group 2)
20
20
0
2
18
17
3
7 (group 3)
15
13
2
1
14
10
5
8 (group 4)
5
5
0
0
5
5
0
9 (group 5)
6
6
0
1
5
6
0
Stage
1
1
0.2818
pT2≥
31
28
3
3
28
23
8
pT3≤
19
17
2
1
18
17
2
Surgical margin
1
1
0.4627
Yes
18
17
1
1
17
13
5
No
32
28
4
3
29
27
5
Lymphovascular invasion
1
1
0.3193
Yes
7
7
0
0
7
7
0
No
43
38
5
4
39
33
10
Biochemical recurrencea
0.3154
1
0.2326
Yes
12
12
0
1
11
8
4
No
37
32
5
3
34
31
6
Age (years), median, range
62 (51-78)
62 (51-78)
64 (54-74)
61.5 (57-69)
62 (51-78)
61.5 (51-78)
63.5 (54-74)
PSA (ng/ml), median, range
7.6 (3.8-50)
8.1 (3.8-50.0)
7.1 (4.2-9.4)
0.3479
7.3 (5.7-10.8)
7.6 (3.8-50.0)
0.1276
8.0 (3.8-19.6)
6.8 (4.2-50)
0.2412
Statistical analysis was performed by using JMP. Fisher’s exact test was used for associations between methylation status or immunostaining of PYCARD and clinicopathological parameters. A two-tailed Student -test was used for associations between methylation status or immunostaining of PYCARD and PSA. aCase no. 37 was excluded from this analysis because postoperative PSA levels did not drop to undetectable levels (0.2 ng/ml).
